Why Shares in DBV Technologies SA Are Soaring 10% Today

After pricing shares of its equity offering at $34, shares in DBV Technologies SA jumped by 10% earlier today.


So what: Since developing new drugs is incedibly expensive, it's not uncommon for clinical stage companies like DBV Technologies to tap equity investors for funding.

In this case, the France-based DBV Technologies plans to sell 3.6 million American Depository Receipts, which at $34 per share should generate $244.8 million in proceeds, before deducting fees, commissions, and other discounts.

That money will be used to advance clinical studies of immunotherapy products that can be applied directly on a patient's skin to treat common food allergies.

DBV Technologies is currently developing Viaskin Peanut and Viaskin Milk as topical thereapies for peanut and milk allergies, respectively.

Viaskin Peanut is currently in a phase 2b follow-up study that is assessing its efficacy and safety across 170 patients with peanut allergies, while Viaskin Milk is about to enter the second part of a phase 1 study.

Now what: DBV Technologies' potential to revolutionize food allergies is massive. According to studies, more than 125,000 people visit emergency rooms in America annually because of food allergies, and roughly 3 million Americans are thought to be allergic to peanuts and/or nuts. As many as twice that number may suffer from milk allergies.

Because no therapies are currently approved for these allergies and they're widespread, some enthusiasm is likely warranted. However, investors should remember that DBV Technologies is still early in the development of these therapies and that means that a lot can still go wrong and derail its shares. Regardless, the company's intriguing enough for me to add it to my watch list.

This $19 trillion industry could destroy the Internet

One bleeding-edge technology is about to put the World Wide Web to bed. And if you act quickly, you could be among the savvy investors who enjoy the profits from this stunning change. Experts are calling it the single largest business opportunity in the history of capitalism... The Economist is calling it "transformative"... But you'll probably just call it "how I made my millions." Don't be too late to the party -- click here for one stock to own when the Web goes dark.

The article Why Shares in DBV Technologies SA Are Soaring 10% Today originally appeared on

Todd Campbell has no position in any stocks mentioned. Todd owns the equity research firm E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .

Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More